Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
09/27 IMMUNOMEDICS : Other Events (form 8-K/A)
09/21 IMMUNOMEDICS INC : Other Events (form 8-K)
09/16 IMMUNOMEDICS : Announces Agreements to Exchange Approximately $80.0 Million of I..
09/15 IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
09/15 Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of ..
09/11 Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMM..
08/30 Immunomedics to Participate in Upcoming Investor Conferences
08/29 INSIDER TRADING ACTIVITY IMMUNOMEDIC : IMMU) – Director Sold 40,000 shares..
08/24 IMMUNOMEDICS : Stock Has Its Sights Set on Higher Prices
08/21 Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govite..
More news
News from SeekingAlpha
10/10 YOUR DAILY PHARMA SCOOP : MannKind Is A Trade Not An Investment; AstraZeneca's I..
09/21 YOUR DAILY PHARMA SCOOP : Intercept's Buy Opportunity, Alcobra's Downfall, Shire..
09/20 IMMUNOMEDICS : 35 Year History Of Failure, IMMU-132 Will Not Receive Accelerated..
09/15 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
09/13 Immunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investmen..
Financials ($)
Sales 2018 18,9 M
EBIT 2018 -94,0 M
Net income 2018 -99,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 71,3x
Capi. / Sales 2019 37,9x
Capitalization 1 348 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 14,2 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Michael R. Garone Chief Executive Officer, CFO & Vice President
Behzad Aghazadeh Chairman
David M. Goldenberg Director, Chief Scientific & Patent Officer
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.199.73%1 348
INCYTE CORPORATION13.88%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP57.01%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522